Onkure Therapeutics Inc expected to post a loss of $1.46 a share - Earnings Preview

Onkure Therapeutics

02/05/2025 14:24

Onkure Therapeutics Inc OKUR.OQ OKUR.O is expected to show no change in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Onkure Therapeutics Inc is for a loss of $1.46 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Onkure Therapeutics Inc is $32.00​, above​ its last closing price of $2.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.74
-1.37
Missed
-85.1
Sep. 30 2024
-1.03
-1.03
-1.10
Missed
-6.8
Jun. 30 2024
-1.00
-1.60
Missed
-60​
Mar. 31 2024
-4.63
-4.37
-2.50
Beat
42.7
​​Dec. 31 2023
-5.57
-5.78
-7.10
Missed
-22.9
Sep. 30 2023
-5.66
-5.71
-5.70
Beat
0.3​
Jun. 30 2023
-5.02
-5.17
-6.50
Missed
-25.8
Mar. 31 2023
-5.93
-6.04
-6.00
Beat
0.7

This summary was machine generated May 2 at 13:24 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)